Sphere Fluidics has announced it is rebranding to Sphere Bio to reflect the company’s transition from a focus on droplet-based microfluidics to a provider of integrated life sciences tools and solutions. 

Founded in 2010, the company has been focused on the development of novel single-cell analysis products and R&D services for a growing portfolio of markets, including biologics discovery, cell therapy and synthetic biology.  

Sphere Bio builds on a track record of over 400 international customers, including collaborations with seven of the world’s Top 10 pharma companies, over £40 million in investment, and a portfolio of 135 international patents. 

The Sphere Bio brand has been introduced to align with the company’s updated identity and strategic vision.  

Following significant operational scale-up and commercial growth over the past two years, including a change in leadership, the rebrand represents expanded market focus and growth potential in impactful and emerging research areas.  

These developments have been driven by demand for Sphere Bio’s portfolio of solutions for single-cell analysis and isolation, including the Cyto-Mine platform and recently launched next-generation Cyto-Mine Chroma platform, alongside new assays to support an increasing range of biotherapeutic applications. 

Dale Levitzke, CEO, Sphere Bio, commented: “Relaunching as Sphere Bio sets the stage for a transformative 2025 – it better represents us as a provider of integrated life sciences tools and solutions, while maintaining a strong basis in engineering. The new name maintains our strong brand recognition, reflecting the growth of the company and its forward-looking approach, paving the way for an exciting future for our team and stakeholders.”

Diana Spencer, Senior Digital Content Editor, DDW